BRIEF — Oxford BioDynamics in new I-O tie-up

Oxford BioDynamics has entered into its fifth collaboration agreement for the development of predictive biomarkers for immuno-oncology (IO) therapeutics.

The UK biotech’s EpiSwitch platform, which identifies and validates epigenetic biomarkers, will be used by an unnamed US company in the collaboration. Financial terms are not disclosed.

Christian Hoyer Millar, chief executive of Oxford BioDynamics, said: “We are pleased to have entered into this new agreement with a major US biopharmaceutical company in the dynamic field of I-O, as there is a high need for the identification of epigenetic biomarkers to evaluate drug performance in therapeutic development programs.

“This agreement represents the fifth contract we have signed in I-O, continuing to validate the potential of our EpiSwitch technology in this space.”